High-priced Genzyme drug is OK'd
1st remedy for rare Pompe disease
Genzyme Corp. won federal approval yesterday for the first drug to treat a rare genetic disorder called Pompe disease, an intravenous treatment that will be one of the most expensive in the world at more than $200,000 per patient annually. (Full article: 1357 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
Waiting for Twitter to feed in the latest...